Andercore | $40,000,000 | (Feb 11, 2026)
Garner Health | $118,000,000 | (Feb 11, 2026)
NATILUS | $28,000,000 | (Feb 11, 2026)
MimiVax, LLC
United States
- Buffalo, NY
- 10/12/2021
- Unknown
- $5,000,000
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
- Industry Pharmaceutical Manufacturing
- Website https://www.mimivax.com/
- LinkedIn https://www.linkedin.com/company/mimivax-llc/
Related People
Michael CiesielskiFounder
United States -
Buffalo-Niagara Falls Area
At MimiVax, our mission is to disrupt cancer. To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.
tem | $75,000,000 | (Feb 11, 2026)
Entire | $60,000,000 | (Feb 11, 2026)
Lema AI | $24,000,000 | (Feb 11, 2026)
ZeroDrift | $2,000,000 | (Feb 11, 2026)
Force Equals | $2,200,000 | (Feb 11, 2026)
Bretton AI | $75,000,000 | (Feb 11, 2026)
Pelgo | $5,500,000 | (Feb 11, 2026)
Newo.ai | $25,000,000 | (Feb 11, 2026)
Equal Parts | $23,000,000 | (Feb 11, 2026)